C
Curevo Vaccine
Biotech & Life Sciences · Seattle, United States · Founded 2017
Creating Next Generation Vaccines For Diseases Of Global Importance MoreLess
Curevo Vaccine is a biotechnology company based in Seattle, specializing in the development of next-generation subunit vaccines for diseases of global health importance. The company’s lead vaccine candidate, CRV 101, is currently under investigation for its safety, tolerability, immunogenicity, and effectiveness in preventing Shingles in older adults. CRV 101 has successfully completed a Phase 1 clinical trial in healthy adults and is now being evaluated for its potential use in immunocompromised children to prevent chickenpox.
Curevo Vaccine operates in the biotech sector, primarily serving healthcare providers, research institutions, and public health organizations. The company’s business model revolves around extensive research and development, clinical trials, and eventual commercialization of its vaccine candidates. Revenue is generated through partnerships, grants, and future sales of approved vaccines.
Keywords: subunit vaccines, biotechnology, Shingles prevention, chickenpox prevention, clinical trials, immunogenicity, safety, tolerability, global health, Seattle.
Company overview
Curevo Vaccine company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2017
- Headquarters
- Seattle, United States
- Employees
- 44
- Open positions
- None listed
- Dealroom signal
- 45.0
Valuation & funding
Curevo Vaccine funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | May 2026 | $0 | — | Eli Lilly | ↗ |
| SERIES BOther financing | Mar 2025 | $110M | $440M | RA Capital Management · Medicxi · OrbiMed · Janus Henderson Investors | ↗ |
| SERIES AOther financing | Nov 2022 | $26M | $300M | RA Capital Management · Adjuvant Capital · Janus Henderson Investors · GC Pharma | ↗ |
| SERIES AOther financing | Jan 2022 | $60M | $240M | RA Capital Management · Janus Henderson Investors · Adjuvant Capital · GC Pharma | — |
Growth signals
Curevo Vaccine website traffic
Latest recorded traffic for Curevo Vaccine is 3.3K monthly website visits, up 0% over the last three months. Curevo Vaccine's team grew 0% over the past year.
Comparisons
Curevo Vaccine compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Curevo Vaccine's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Curevo Vaccine has talent and traffic
team presence
In the news
Latest news about Curevo Vaccine
Recent press, funding announcements, and product moves mentioning Curevo Vaccine — open to read from the original sources.
Market sentiment
What the market is saying about Curevo Vaccine
An AI-synthesized read of the highest-engagement posts about Curevo Vaccine on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Curevo Vaccine’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.